Cover Image

A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma

The development of resistance to tyrosine kinase inhibitors (TKIs) in metastatic non-small cell lung cancer (NSCLC) with oncogenic driver mutations highlights the challenge in improving the survival of these patients. The standard of care for ALK-rearranged advanced NSCLC refractory to various gener...

Full description

Saved in:
Bibliographic Details
Main Authors: Von, Cheong E., Fuang, Ho Gwo
Format: Article
Published: Elsevier 2021
Subjects:
R Medicine
R Medicine (General)
RA Public aspects of medicine
RC Internal medicine
Online Access:http://eprints.um.edu.my/34895/
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.eprints.34895
record_format eprints
spelling my.um.eprints.348952022-09-08T04:18:08Z http://eprints.um.edu.my/34895/ A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma Von, Cheong E. Fuang, Ho Gwo R Medicine R Medicine (General) RA Public aspects of medicine RC Internal medicine The development of resistance to tyrosine kinase inhibitors (TKIs) in metastatic non-small cell lung cancer (NSCLC) with oncogenic driver mutations highlights the challenge in improving the survival of these patients. The standard of care for ALK-rearranged advanced NSCLC refractory to various generations of ALK TKIs falls back to the use of chemotherapy and the prognosis remains poor. We report the case of a 41-year-old lady with an ALK-translocated metastatic lung adenocarcinoma, who demonstrated good response to an immune checkpoint inhibitor, atezolizumab in combination with bevacizumab and chemotherapy (pemetrexed and carboplatin), following disease progression on three generations of ALK TKIs. Six months into treatment, she continues to show improvement in her health-related quality of life and is tolerating treatment well. Our case suggests that this treatment regimen is a potential treatment option for TKI-refractory driver-mutated NSCLC. Elsevier 2021 Article PeerReviewed Von, Cheong E. and Fuang, Ho Gwo (2021) A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma. Respiratory Medicine Case Reports, 34. ISSN 2213-0071, DOI https://doi.org/10.1016/j.rmcr.2021.101478 <https://doi.org/10.1016/j.rmcr.2021.101478>. 10.1016/j.rmcr.2021.101478
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
topic R Medicine
R Medicine (General)
RA Public aspects of medicine
RC Internal medicine
spellingShingle R Medicine
R Medicine (General)
RA Public aspects of medicine
RC Internal medicine
Von, Cheong E.
Fuang, Ho Gwo
A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
description The development of resistance to tyrosine kinase inhibitors (TKIs) in metastatic non-small cell lung cancer (NSCLC) with oncogenic driver mutations highlights the challenge in improving the survival of these patients. The standard of care for ALK-rearranged advanced NSCLC refractory to various generations of ALK TKIs falls back to the use of chemotherapy and the prognosis remains poor. We report the case of a 41-year-old lady with an ALK-translocated metastatic lung adenocarcinoma, who demonstrated good response to an immune checkpoint inhibitor, atezolizumab in combination with bevacizumab and chemotherapy (pemetrexed and carboplatin), following disease progression on three generations of ALK TKIs. Six months into treatment, she continues to show improvement in her health-related quality of life and is tolerating treatment well. Our case suggests that this treatment regimen is a potential treatment option for TKI-refractory driver-mutated NSCLC.
format Article
author Von, Cheong E.
Fuang, Ho Gwo
author_facet Von, Cheong E.
Fuang, Ho Gwo
author_sort Von, Cheong E.
title A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
title_short A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
title_full A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
title_fullStr A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
title_full_unstemmed A case of remarkable response to atezolizumab in ALK-translocated metastatic lung adenocarcinoma
title_sort case of remarkable response to atezolizumab in alk-translocated metastatic lung adenocarcinoma
publisher Elsevier
publishDate 2021
url http://eprints.um.edu.my/34895/
_version_ 1744649199715090432
score 13.211869

Similar Items